Step 1 of 2
These slides illustrate the rapidly evolving role of bispecific antibodies (BsAbs) in multiple myeloma, with a focus on BCMA- and GPRC5D-directed therapies, their mechanisms of action, pivotal and emerging clinical trial data, and characteristic safety considerations such as cytokine release syndrome, neurotoxicity, infection risk, and target-specific adverse events. The slide deck also illustrates BsAb combination regimens, sequences after prior BCMA-directed therapy, potential mechanisms of treatment failure, and the relative clinical and logistical considerations of BsAbs vs CAR T-cell therapy. The slide set in this module helps visually conceptualize where BsAbs may fit within individualized treatment strategies for patients with relapsed/refractory multiple myeloma.